View Older Stories View More Recent Stories
-
Edwards Lifesciences (EW) PT Raised to $71 at Canaccord Genuity
-
Stifel Reiterates Buy Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Tops Q4 EPS by 4c, Offers Guidance
-
Stifel Upgrades Edwards Lifesciences (EW) to Buy
-
Wolfe Research Downgrades Edwards Lifesciences (EW) to Underperform
-
Grabar Law Office Investigates Claims on Behalf of Shareholders of Edwards Lifesciences Corporation (EW)
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
BofA Securities Upgrades Edwards Lifesciences (EW) to Buy
-
EW DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important December 13 Deadline in Securities Class Action - EW
-
Faruqi & Faruqi Reminds Edwards Lifesciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 - EW
-
EW DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Edwards Lifesciences Corporation Investors with Losses in Excess of $100k to Secure Counsel Before Important December 13 Deadline in Securit
-
Edwards Lifesciences (EW) PT Raised to $75 at TD Cowen as '25 Outlook Meets Expectations'
-
Bernstein SocGen Group Reiterates Market Perform Rating on Edwards Lifesciences (EW), 'Bullish Investor Day'
-
RBC Sees 'Multi-Year Growth Runway' for Edwards Lifesciences (EW); PT Raised
-
Edwards Lifesciences (EW) PT Raised to $78 at Truist Securities
-
Edwards Lifesciences (EW) PT Raised to $68 at Canaccord Genuity
-
Oppenheimer Reiterates Outperform Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) Outlines Growth Strategy
-
RBC comments on medical devices sector ahead of EW's Investor Day
-
Piper Sandler Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Citi Removes Two names from 90-Day Catalyst Watch Lists
-
Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
-
BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW): TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
-
TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW): Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients
-
Edwards Lifesciences (EW) Quickly Falls to Low
-
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
-
Edwards Lifesciences (EW) PT Lowered to $70 at Piper Sandler
-
Edwards Lifesciences (EW) PT Lowered to $63 at Canaccord Genuity
-
TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) PT Lowered to $70 at Truist Securities
-
BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
After-hours movers: Capri Holdings, Skechers, DexCom, Western Digital and more
-
Edwards Lifesciences (EW) Tops Q3 EPS by 1c; offers guidance
-
Edwards Lifesciences (EW) PT Raised to $73 at Baird
-
Morgan Stanley Resumes Edwards Lifesciences (EW) at Equalweight
-
Piper Sandler Reiterates Neutral Rating on Edwards Lifesciences (EW)
-
Edwards Lifesciences (EW) PT Lowered to $66 at Canaccord Genuity
-
TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Jefferies Downgrades Edwards Lifesciences (EW) to Hold
-
After summer drubbing, Edwards Lifesciences (EW) said targeted in takeover - source
-
Edwards Lifesciences (EW) Ticks Higher on Unconfirmed Market Chatter
-
Edwards Lifesciences (EW) PT Lowered to $71 at Truist Securities
-
Edwards Lifesciences (EW) PT Lowered to $80 at Barclays
-
Edwards Lifesciences (EW) PT Lowered to $80 at Barclays
-
Edwards Lifesciences (EW) PT Lowered to $80 at Wells Fargo
-
Citi Opens 90-Day Upside Catalyst Watch on Edwards Lifesciences (EW)
